Diligence memo · auto-generated · as of July 2, 2026

Health Platforms, Inc.

Health Platforms, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Health Platforms, Inc. operates in Healthtech, based in NEW YORK.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Health Platforms, Inc. has raised $5.8M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $5.0M on 2016-12-16.

Most recent recorded round closed around 2016-12-16.

Valuation (modeled)modeled

Provath models Health Platforms, Inc. at approximately $113M (range $6.4M–$614M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.84× the median modeled value of Series A Healthtech companies in 2016–2018 (103 peers) — value vs value, same stage and era. Within the normal band (84% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 11 months.

Last raise 9.5 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 23.3× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 60% of Healthtech peers (2138 compared).

Modeled value ranks above 79% of those peers.

Closest niche peers: Prenexus Health, LLC, HealthMyne, Inc., Companion Medical, Inc., Health at Scale Corp, Motus GI Medical Technologies, Ltd..

Peoplefiled

6 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.